While we wait for the news that 250 MACE events have occurred, there are a couple financial matters what will be somewhat interesting to watch in the next few weeks.

Firstly the Hepalink licencing agreement ends on April 15th, I think we all expect it will just be extended to a date far enough in the future that both parties have visability on what they have ( or hopefully, dont have).

The second is on May 4th the Third Eye loan becomes due. That one is a little more interesting, in that it will tell us whether 1/2 the recent PP was applied to the loan, which is the legal obligation and has occured upon each raise (which then likely means RVX will need at least a small raise again before the results) and whether RVX has to pay the remaining $7.5 mill or so outstanding before May 4th (assuming half he recent PP went to the loan) or is the loan extended by Third Eye and if so, what consideration is paid in warrants etc. One would wonder why Third Eye would want to leave any rsik on the table when they have a ton of free shares/warrants, but someone mentioned somethign about another entity funding part of their loan, so who knows what is going on behind the scenes.

So while I am sure all this will sort itsef out, will be interesting to see in what manner.